Clinical Trial

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Study acronym: DME
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Protocol Amendment History 6 changes
notable Trial sites expanded: 62 -> 68 locations 2026-07-07
notable Trial sites expanded: 48 -> 62 locations 2026-06-04
notable Trial sites expanded: 38 -> 48 locations 2026-05-07
notable Trial sites expanded: 12 -> 38 locations 2026-04-08
notable Primary completion pushed: 2027-08 -> 2027-10 2026-04-08
minor Completion pushed: 2028-08 -> 2028-10 2026-04-08
Trial Details
NCT Number NCT07449923
Lead Sponsor EyePoint Pharmaceuticals, Inc.
Conditions Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
Enrollment 240 participants
Start Date 2026-02-09
Primary Completion 2027-10 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-04